PDCD1 and neoplasm: Mechanistically, it is possible that anti-PD-1 monoclonal antibodies are more likely to induce pulmonary adverse events in combination with radiotherapy because PD-L1 is expressed on the surface of tumor cells, and radiotherapy toxicity is more likely to cause damage and abnormal inflammatory responses in normal tissues [65].